A Manually Curated Database on Clinical Studies Involving Cell Products Derived from Human Pluripotent Stem Cells by Kobold, Sabine et al.
Stem Cell Reports
ArticleA Manually Curated Database on Clinical Studies Involving Cell Products
Derived from Human Pluripotent Stem Cells
Sabine Kobold,1,6 Anke Guhr,1,6 NancyMah,2 Nils Bultjer,2 Stefanie Seltmann,2 Andrea E.M. SeilerWulczyn,1
Glyn Stacey,3,4,5 Hao Jie,4 Wang Liu,4 Peter Lo¨ser,1,* and Andreas Kurtz2,3,*
1Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany
2BCRT - Berlin Institute of Health Center for Regenerative Therapies, Berlin-Brandenburg Center for Regenerative Therapies, Charite´ Universita¨tsmedizin
Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
3International Stem Cell Banking Initiative, 2 High Street, Barley, Herts SG8 8HZ, UK
4National Stem Cell Resource Centre, Institute of Zoology, Chinese Academy of Sciences, Beijing 100190, China
5Innovation Academy for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China
6Co-first author
*Correspondence: loeserp@rki.de (P.L.), andreas.kurtz@charite.de (A.K.)
https://doi.org/10.1016/j.stemcr.2020.06.014SUMMARYThe last 5 years have witnessed a significant increase in the number of clinical studies based on human pluripotent stem cells (hPSCs). In
parallel, concern is increasing about the proliferation of unregulated stem cell treatments worldwide. Regulated clinical testing is a de
facto standard to establish the safety and efficacy of new cell therapies, yet reliable information on clinical studies involving hPSCs is
scattered. Our analysis of a multitude of resources found 54 clinical studies involving several types of hPSCs, which are performed in
ten countries. While the majority of those studies is based on human embryonic stem cells (hESCs), clinical studies involving human
induced pluripotent stem cells increased more strongly in the past 2 years than the number of hESC-based studies. A publicly accessible
database was created using the human pluripotent stem cell registry (https://hpscreg.eu) platform, providing a steadily updated compre-
hensive overview on hPSC-based clinical studies performed worldwide.INTRODUCTION
Very soon after the first derivation of human pluripotent
stem cell (hPSC) lines more than 20 years ago (Thomson
et al., 1998), there were hopes in the scientific community
that these cells could be the basis for future cell and tissue
replacement therapies (Trounson and Pera, 2001). Over the
past two decades, progenitor or somatic cells derived from
hPSCs proved to be functional after transplantation in ani-
mals and could therefore serve as cell/tissue replacement in
the treatment of a wide range of human degenerative dis-
eases. Although the prospective clinical use of hPSC-derived
cells/tissues still faces a range of safety, quality, functionality,
and efficacy issues that need to be solved, a first safety study
involvinghuman embryonic stemcell (hESC)-derived oligo-
dendrocyteprogenitors for treatmentof subacute spinal cord
injury was already launched in 2007 and approved in 2009,
after years of delay and a gargantuan22,000-plus page Inves-
tigationalNewDrugapplication (Alper, 2009; Pollack, 2010).
This study was followed by the first hESC-based clinical
studies for treatment of macular degeneration (Liu et al.,
2018; Schwartz et al., 2012, 2015; Song et al., 2015; Vitillo
et al., 2020) with some early positive indications after 2–3
years of follow-up (https://theophthalmologist.com/
subspecialties/a-promise-fulfilled), diabetesmellitus (Schulz,
2015), and ischemic heart disease (Menasche et al., 2018).
With the establishment of the first human induced
pluripotent stem cells (hiPSCs) in 2007 (Takahashi et al.,546 Stem Cell Reports j Vol. 15 j 546–555 j August 11, 2020 j ª 2020 The A
This is an open access article under the CC BY-NC-ND license (http://creativ2007; Yu et al., 2007), the prospectwas held out that hiPSCs
would facilitate personalized cell therapies for treating hu-
man diseases while solving the controversy over the
destruction of embryos in the process of deriving hESCs.
Indeed, due to strong promotion of hiPSC research espe-
cially in Japan, a first autologous hiPSC-based clinical study
was initiated in 2014 for the treatment of age-related mac-
ular degeneration (Mandai et al., 2017), and shortly there-
after a whole battery of further clinical trials involving
hiPSC-derived cells were either announced or initiated.
Since the translation of hPSC research to the clinic
started in 2010, we and others have begun to systematically
analyze and document the respective clinical studies to
assess the progress in this field and provide an overview
on planned, completed, and ongoing hPSC-based clinical
trials (Desgres and Menasche, 2019; Guhr et al., 2018).
Here we present the up-to-date status on the extent, sub-
ject, and localization of hPSC-based clinical studies
currently under way and provide an easily accessible refer-
ence database on hPSC-based clinical studies. Data were
collected from a multitude of publicly accessible sources
such as clinical trial registries worldwide, press releases,
and scientific papers, and a respective database was estab-
lished, which is hosted on the hPSCreg platform (https://
hpscreg.eu/browse/trials). This novel database combines
data from relevant national and international clinical trial
registries, provides for a constantly updated and compre-
hensive overview on the type of clinical studies, and alsouthors.
ecommons.org/licenses/by-nc-nd/4.0/).
links clinical studies to the hPSC lines onwhich a cell or tis-
sue therapy product is based. The criteria adopted to test
the veracity of included data is discussed in terms of estab-
lishing minimum standards and necessary criteria for such
international databases and ongoing refinement of the
hPSCreg database.RESULTS
Current State of hPSC-Based Clinical Studies
Having studied research trends in the field of hPSCs over
the past 15 years (Guhr et al., 2006, 2018; Kobold et al.,
2015; Lo¨ser et al., 2010, 2012), we were now interested in
tracing the latest developments of translating hPSC
research to the clinic. Because of a lack of a comprehensive
access platform for information on clinical studies, we
searched clinical trial databases, press releases, scientific ar-
ticles, and web pages of companies involved in hPSC
research for novel clinical study data on a regular basis
(for details see Experimental Procedures). Based on this
continuous intensive long-term collection of publicly
available information, we compiled a unique database of
verified clinical studies based on hPSCs, including hESCs,
hiPSCs, stem cells created by somatic cell nuclear transfer
(SCNT-hPSCs), and parthenogenetically derived human
pluripotent stem cells (hpPSCs).
A summary of our data is shown in Table 1. By the end of
2019, there were reports on at least 54 clinical studies based
on hPSCs aimed at treating 22 different diseases. It should
be noted that all of these 54 studies include the transfer of a
cell product to patients. Other studies also listed in regis-
tries such as clinicaltrials.gov and which, for example,
only plan the production of patient-specific clinical-grade
hPSC lines, were excluded from our analyses.
Nearly half of these studies (n = 24) aim to develop new
therapies for eye diseases, mainly for different kinds of
macular degeneration and retinal dystrophies. It is not sur-
prising that the eye is the major target of first hPSC-based
trials in humans, since it is immune-privileged, is easily
accessible for transplantation, and capable of direct obser-
vation for assessment of engraftment. Moreover, differenti-
ation of retinal pigment epithelia cells is highly efficient,
and therapeutic effects in the eye may require only a rather
small number of cells, reducing the risks of tumorigenicity
(Zarbin et al., 2019). In addition, transplants in the eye can
be monitored non-invasively, allowing for detection of po-
tential aberrations at an early stage. Beyond that, macular
degeneration in particular is a very frequent disease in
the developed world, and adequate therapies are not avail-
able. The next most popular indications for hPSC-derived
cell therapy were aimed at diabetes mellitus (four clinical
studies sponsored by Viacyte) and ischemic heart diseases(also four studies): both diseases also represent major
health problems in Western countries. Other clinical
studies performed so far aim to treat neoplasms, neuronal
degenerative diseases such as Parkinson’s disease, or spinal
cord injuries. Details of all 54 clinical trials are given in
Table S1.
While 32 of the clinical studies identified are performed
with hESC-derived cell products, 19 studies are based on
hiPSCs. Figure 1 shows the temporal distribution of the
initiation of hESC- and hiPSC-based clinical studies within
the past 10 years. Not surprisingly, since hESCs entered the
field nearly 10 years before hiPSCs, hESC-based cell prod-
ucts found their way into clinical trials earlier than hiPSCs.
However, while the annual number of newly started hESC-
based clinical studies did notmarkedly increase after 2014–
2015, we observed a significant increase in hiPSC-based
studies initiated in the last 2-year period analyzed here
(from only two new studies in 2016–2017 to 14 new studies
in 2018–2019). In addition, there are two clinical studies in
which a cell product based on hpPSCs is tested in patients
with Parkinson’s disease and one study in which retinal
pigment epithelial cells derived from SCNT-hPSCs are
used for treatment of dry age-relatedmacular degeneration.
Clinical studies based on hPSC are being performed in at
least ten countries (Figure 2). Most studies were initiated in
the United States and China, with at least 16 clinical trials
started until the end of 2019 in each of these two countries.
Clinics in the United Kingdom as well as in Canada are
involved in six and four hESC-based clinical trials, respec-
tively, while seven clinical studies based on hiPSCs were
or are being performed in Japan. It should be noted that
the number of clinical studies initiated in the respective
countries correlates with the national research activities
in the hPSC field (reported in Guhr et al., 2018), indicating
that intensively funded basic research is the basis for the
successful development of cell products for clinical use.
It is also of interest to know from which specific hPSC
line the cell product used in a given clinical trial was devel-
oped: the use of cell products derived from a particular cell
line in numerous trials would increase the body of data to
establish a safe history of use and promote the exchange
and harmonization of applicable quality requirements be-
tween different lines. While there is only scarce data pub-
licly available as to which specific cell lines were used in
hiPSC-based studies, this information can be provided for
most (27 out of 32) hESC-based trials (Table 2). According
to data publicly available, cell products derived from
hESC line MA09 were used in 11 studies, which all aim at
therapy development for degenerative eye diseases, while
16 studies are based on one of the nine other hESC lines
listed in Table 2. Of the ten known hESC cell lines used as
a starting material for cell products to be transferred into
patients, four cell lines (HDAC100, HDAC112, Q-CTS-Stem Cell Reports j Vol. 15 j 546–555 j August 11, 2020 547
Table 1. Clinical Trials on the Basis of hPSCs by the End of 2019
ICD-10 Main Chapter Disease ICD-10
Cellular Origin of Cell Product
hESC hiPSC hpPSC SCNT-hESC Total
Neoplasms malignant neoplasms (advanced solid
tumors)
0 2 0 0 5
malignant neoplasm of bronchus and lung 1 0 0 0
myeloid leukemia 0 1 0 0
Diseases of the blood and blood-forming
organs and certain disorders involving the
immune mechanism
beta-thalassemia 0 2 0 0 2
Endocrine, nutritional, and metabolic
diseases
type 1 diabetes mellitus 4 1 0 0 6
primary ovarian failure 1 0 0 0
Diseases of the nervous system Parkinson’s disease 0 3 2 0 6
motor neuron disease 1 0 0 0
Diseases of the eye and adnexa other retinal disorders 4 0 0 0 25
degeneration of macula and posterior pole:
senile macular degeneration, dry age-related
macular degeneration
10 1 0 1
hereditary retinal dystrophy: Retinitis
pigmentosa
2 0 0 0
hereditary retinal dystrophy: Stargardt
disease
5 0 0 0
other specified disorders of cornea (limbal
stem cell deficiency)
0 1 0 0
degeneration of macula and posterior pole:
wet age-related macular degeneration
0 1 0 0
Diseases of the circulatory system ischemic heart diseases 1 4 0 0 7
cerebral infarction, unspecified 0 2 0 0
Diseases of the musculoskeletal system and
connective tissue
derangement of meniscus due to old tear or
injury
1 0 0 0 1
Injury, poisoning, and certain other
consequences of external causes
injury of spinal cord, level unspecified 2 0 0 0 3
bone marrow transplant rejection 0 1 0 0
32 19 2 1 54
Given are diseases targeted by the respective studies and the number of studies involving hESC-, hiPSC-, hpPSC-, and SCNT-hESC-derived cell products. Two
Food and Drug Administration-approved hESC studies withdrawn before enrollment are not included.hESC-2, and RC-09) were originally derived as clinical-
grade cell lines or as GMP-compliant cell lines, respectively
(Kaupisch et al., 2012; Liu et al., 2018; Tannenbaum et al.,
2012). The remaining six hESC lines were established as
laboratory-grade lines and were only retrospectively con-
verted into clinical-grade material (Amit and Itskovitz-El-
dor, 2002; D’Amour et al., 2006; Draper et al., 2004; Lund
et al., 2006; Thomson et al., 1998). In this context it should
be noted that the use of standard pluripotent stem cell line548 Stem Cell Reports j Vol. 15 j 546–555 j August 11, 2020names, as promoted by hPSCreg (Seltmann et al., 2016),
would enable unambiguous and transparent tracking of
these clinically important lines from research to clinical
application.
Although there are no detailed data publicly available on
the specific hiPSC lines used as a starting material for the
production of hiPSC-derived cells/tissues used in clinical
trials, information on the autologous or allogenic use of

































Figure 1. Temporal Distribution of the
Initiation of Clinical Studies Based on
either hESCs or hiPSCs within the Past
10 Yearsthis information, in 8 out of 19 studies (mainly based in
China), autologous hiPSCs were used to produce the cell
product for transplantation, whereas in 11 cases allogenic
cells were used as a starting material. The allogenic use of
hiPSC-derived cell products may reflect the growing reali-
zation that patient-specific therapies using personalized
cell products is currently extremely expensive and time-
consuming and therefore may not be broadly applicable
in the near future.
The Clinical Studies Database on hPSCreg
Currently there is no publicly available comprehensive
overview on hPSC-based clinical trials, and collecting the
relevant scattered information is cumbersome. The lack
of information access and transparency may hamper clin-

























Figure 2. hPSC-Based Clinical Studies by Countries Worldwide
Shown is the number of clinical trials based on either hESCs or
hiPSCs which were performed/initiated within the past decade.
*Several studies were/are performed in more than one country so





Therefore, we initiated a clinical study database tomeet the
need for easily accessible comprehensive and up-to-date in-
formation on clinical studies. This database is part of the
Human Pluripotent Stem Cell Registry (hPSCreg) platform,
a global and freely accessible registry for hPSC lines that has
been progressively developing its procedures for manage-
ment of ethical and scientific data since 2006 (Isasi et al.,
2019; Seltmann et al., 2016).
The aim of the clinical study database is to provide a regu-
larly updated overview on planned, ongoing, and
completed clinical studies in which cell products derived
from hPSCs, including hESCs, hiPSCs, SCNT-hPSCs, or
hpPSCs, are tested in patients. Therefore, the database com-
prises only those trials where a stem cell-based product is
used to treat patients as well as the respective (observa-
tional) follow-up studies. Some other clinical study data-
bases/registries list, for example, the donation of tissues
aimed to generate clinical-grade hiPSC lines (and therefore
involve patients as donors and not as recipients of cells/tis-
sues). These data are excluded from the clinical study
database.
Although it is envisaged to provide a broad range of infor-
mation on hPSC-based clinical studies, available data are
sometimes restricted. As a consequence and to ensure a
specified data consistency, a minimum information pack-
age was defined and is stringently required, including a
meaningful study title, current study phase, starting date,
estimated number of participants, and recruitment status.
Furthermore, a contact including name and email address
is required together with listing information about the per-
son, company, or organization that takes responsibility forStem Cell Reports j Vol. 15 j 546–555 j August 11, 2020 549
Table 2. hESC Lines Used for Production of Cell Products Used in Clinical Trials So Far
hESC Line (Provider) hESC Line (hPSCreg) First Publication of Cell Line No. of Clinical Trials
MA09 ACTe002-A 2006 11
Cyt49 VCYTe001-A 2006 4
H1 WAe001-A 1998 3
H9 WAe009-A 1998 2
Shef-1 AXORe001-A 2004 2
HADC102 HADe008-A 2012 1
HADC100 HADe007-A 2012 1
I6 TECHe003-A 2002 1
Q-CTS-hESC-2 not yet registered 2016 1
RC-09 RCe013-A 2012 1
Data NA 5
Given are the provider’s and hPSCreg’s designation of hESC lines, the year of its first publication in the scientific literature, and the number of clinical trials
based on the respective cell line. Please note that for five studies performed in China, cell line information cannot be provided.the initiation, management, and/or financing of the clin-
ical trial (‘‘sponsor’’). The database also provides links to
the full original source public records (e.g., to the respective
record in the primary registries as listed in the ‘‘material
andmethods’’ sections) to facilitate the identification of tri-
als by joiningmultiple records on the same trial. Currently,
the database provides detailed information on 42 studies
involving hPSC-derived material. To ensure consistent
and valid data, the remaining 12 studies identified so far
will only be included after all information required for
listing in the database is obtained.
In addition to the obligatory information, a range of
further data is included, for example on the specific aims
with regard to the disease targeted by the respective cell
product. Moreover, the original hPSC line on which a study
is based, the name of cell or tissue product used in the study,
and published scientific papers connected to a given clinical
trial are listed. This latter information will provide links to
the extensive data on hPSC lines registered in hPSCreg as
well as to the comprehensive collection of scientific papers
on derivation and use of hPSC lines present in hPSCreg.
Currently, information on clinical studies from publicly
available national and international registries is manually
curated by hPSCreg staff to ensure that data are recorded
in a consistent manner. In addition, hPSCreg seeks the
participation of principal investigators/sponsors of the
respective studies to confirm the clinical study records
whenever possible. Furthermore, voluntary text/uploads
are possible, for example to better describe the clinical
study and its outcomes or to provide more details on the
potency assays and safety testing for the used hPSC lines550 Stem Cell Reports j Vol. 15 j 546–555 j August 11, 2020as well as their derivatives. Records reconfirmed by the
qualified investigator in charge of a given study aremarked,
indicating the extra level of validation. This process of data
validation assures that registered data in hPSCreg are com-
plete, accurate, and valid.
Figure 3 shows a screenshot of the searchable interface
that currently displays all studies indexed in the database
by descending study name as default. Currently, a sorting
function allows displaying of the indexed studies by study
name as well as starting and ending dates. For the future,
additional filter options are planned so that it will be
possible to find studies by study name, disease indication,
sponsors, keywords, the hPSC line on which a given study
is based, and scientific papers linked to a specific clinical
trial.DISCUSSION
Reliable information about ongoing clinical studies using
hPSCs is required to assess the development and progress
made in the field, which hasmade promises of cures for un-
treatable diseases. This is relevant to realistically informnot
only the public but also translational researchers, regula-
tors, and stakeholders. The provision of dependable, vali-
dated knowledge makes it also more difficult for dubious
stem cell clinics to be successful. Moreover, during this
early stage of clinical study development it is of high rele-
vance to have information available on the cells being
used and their characterization, quality assessment, appli-
cation areas, details on clinical study design, recruitment,
Figure 3. Screenshot of the Clinical Study Database for hPSC-Based Cell Therapies Interface
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treatment, and the applicable regulatory and ethical back-
grounds. This information should be presented in a way
that would allow for at least a basic level of comparative-
ness and insights into developing standards. However,
such information is currently not findable and accessible
in a comprehensive, focused way but rather scattered in
multiple databases and registries, and punctually described
in some publications on planned and ongoing clinical use
of hPSC-derived cell products for specific clinical applica-
tions (Parmar et al., 2020; Senior and Pettus, 2019; Silvestro
et al., 2020; Wattanapanitch, 2019). Therefore, we have
collected information on clinical studies from a wide array
of sources. As reported previously for searching of literature
(Guhr et al., 2018; Kobold et al., 2015), scouting clinical
study databases or the web by the mere use of keywords
without manual review of results for validation will result
in a significant amount of false-positive results. For
example, screening of clinicaltrials.gov with terms such
as ‘‘embryonic stem cells’’ or ‘‘induced pluripotent stem
cells’’ resulted in nearly 160 alleged clinical studies
involving these cell types and would cause a considerable
overestimation of the actual number of clinical studies
registered. Instead, we identified 53 unique and actual clin-
ical studies from the scouted resources, conducted in ten
countries. However, this numbermight be an underestima-
tion, as our searches rely mostly on English-language re-
sources. Interestingly, 29 of the 53 clinical studies were
sponsored by nine commercial entities. These companies
sponsored clinical studies mainly for eye diseases and dia-
betes mellitus; study indications included spinal cord
injury, amyotrophic lateral sclerosis, Parkinson’s disease,
and ischemic stroke, among others.
Not surprisingly, the majority of the studies performed
are using hESCs as source material; only in the period
2018–2019 did the number of new studies using hiPSCs
exceed those using hESCs as starting material. At least ten
specific hESC lines were identified to be used in 27 clinical
studies, while no information on the specific hESC line
used as starting material could be acquired for five studies.
In contrast to hESCs, for allogenic application of hiPSC-
based cells (n = 11), none of the lines were unambiguously
identifiable for the recorded studies. Thus, there is some
lack of information with respect to the source material
used especially for the clinically used hiPSC lines. However,
information on cell lines used may be very valuable, as
would be information about applied quality control and
testing regimens for these cells and the differentiated ther-
apeutic cell products. In addition, findability of clinically
applied hPSC lines would be markedly increased by conse-
quently using standard identifiers for these cell lines (Kurtz
et al., 2018).
To make the clinical studies more findable and data on
these accessible and interoperable, we establish a dedi-552 Stem Cell Reports j Vol. 15 j 546–555 j August 11, 2020cated database for hPSC-based clinical studies. This data-
base uses the hPSCreg platform and thus provides links
to the data resources on hPSC lines registered in this data-
base. As much as possible, standardized nomenclatures
and ontologies are used for description of information
to improve interoperability. Clinical studies in the data-
base will be interlinked to other public resources hosting
information on the same trial, thus creating a rich
network of data. To be robust and thus reliable, the infor-
mation provided on clinical studies in the hPSCreg data-
base must satisfy a set of minimal criteria to be registered
in the database and be validated for public access. This is
required to allow for a meaningful evaluation and com-
parison of data. Preferentially, clinical study data obtained
through the described search algorithms are manually
entered by the hPSCreg team, which seeks verification
by the team performing the respective clinical studies.
In addition, data and information can be entered to
enrich the information on a specific study, although all
data will be independently validated by the hPSCreg to
maintain a high level of reliability and completeness.
The database does also allow for registration of new clin-
ical studies by hPSCreg registered users. However, to
ensure a high quality of the clinical study database, all
newly entered studies will be manually verified by the
hPSCreg and by the investigators performing the respec-
tive clinical studies before their public release. To assure
transparency of database content development and
reduce the risk of faulty transcription, the used standard
protocols for data entry will be made available on the
hPSCreg website.
The resource described here may be used for periodic
updates to track trends over time regarding hiPSC,
hESC, or other hPSC type of clinical use, type of prod-
uct, potency and safety assays, commonly used cell
lines, and quality assessment, and thus provide a plat-
form for exchange of information. The clinical studies
database at hPSCreg aims not to replace but rather to
supplement established registries such as the World
Health Organization (WHO) registry, which has an in-
ternational regulatory utility and governance function.
The main benefits of having a transparent overview
on past and ongoing clinical studies with hPSCs is
the mutual exchange of information, a platform for
comparing and finding of applied standards and assays
and to analyze trends in the field. Eventually, it may be
used for comparison with other non-hPSC-based cell
therapies. Finally, the high level of reliability and vali-
dation of information makes it a resource to distin-
guish studies having proper regulatory oversight from
those aimed at providing commercial non-regulated
clinical applications or treatments without proven ther-
apeutic and safety profiles.
EXPERIMENTAL PROCEDURES
Retrieving the Number of Clinical Studies Involving
hPSCs
Identification of clinical studies was performed as described previ-
ously (Guhr et al., 2018). Please note that both terms ‘‘clinical
study’’ and ‘‘clinical trial’’ were used to identify clinical studies/tri-
als from public sources and include also designations such as clin-
ical research studieswithin a regulated environment; therefore, the
terms clinical study and clinical trial are used synonymously to
describe a clinical application in a regulatory framework (see also
Li et al., 2014).
In brief, the following resources were sourced: ClinicalTrials.gov,
by the USNational Library ofMedicine (https://clinicaltrials.gov/),
International Clinical Trials Registry Platform of theWHO (http://
apps.who.int/trialsearch/), University Hospital Medical Informa-
tion Network (UMIN), Japan (https://www.umin.ac.jp/ctr/), Chi-
nese Clinical Trial Registry (ChiCTR), China (http://www.chictr.
org.cn/searchprojen.aspx), the EU Clinical Trials Register by the
European Medicines Agency, the Netherlands (https://www.
clinicaltrialsregister.eu/ctr-search/search), German Clinical Trials
Register (Deutsches Register Klinischer Studien [DRKS]) by the
German Institute for Medical Documentation and Information,
Germany (https://www.drks.de/drks_web/).
In addition, the sponsor’s web pages were evaluated for the addi-
tional information on the respective clinical trials, and public infor-
mation in the press was obtained by regular examination of Google
NewsAlerts containing the terms stem cellor stem cells and clinical tri-
als. Moreover, stem cell newsletters, such as Stem Cell Research News
and Stem Cell Business News (published every 2 weeks by DataTrends
Publications) were monitored on a regular basis. Extensive searches
of the scientific literature were frequently performed in the PubMed
databaseaccessible throughtheNIHNationalLibraryofMedicineus-
ing the search strings described in Kobold et al. (2015), supple-
mented by the terms ‘‘clinical stud*’’ or ‘‘clinical trial*.’’Establishing the Clinical Study Database
Theclinical studydatabase isembedded in thehPSCregplatform. It is
a web application composed of a user interface provided by an inter-
mediary server application, which accesses the data storage through
Java/Tomcatweb services. The clinical study database describedhere
uses the same technologies that hPSCreg employs and crosslinks to
relevant information available in hPSCreg and worldwide clinical
trial registries, includingClinicalTrials.gov (United States), European
Union Drug Regulating Authorities Clinical Trials Database (Eu-
draCT), the University Hospital Medical Information Network Clin-
ical Trials Registry (UMIN-CTR; Japan), the ChiCTR (China), and the
InternationalClinical Trials RegistryPlatform(WHO).Todefineclin-
ical features and cell types, ontologies are used, including Orphanet
Rare Disease Ontology, Disease Ontology, and Experimental Factor
Ontology for clinical features, as well as Cell Ontology and Founda-
tional Model of Anatomy for cells or anatomic locations.
The interface for recording the study information was designed
to include the majority of the Trial Registration DataSet (TRDS)
fields as defined by the International Standards for Clinical Trial
Registries (https://apps.who.int/iris/handle/10665/274994). To
increase data interoperability, hPSCreg stores existing clinical trialidentifiers from other databases, such as NCT identifiers, EudraCT
number, or sponsor-supplied identifiers.Management, Maintenance, and Updating of
Database
Initial datasets are sourced from international and national clinical
trial registries that participate in the WHO Registry Network,
whose members must adhere to the WHO Registry criteria, some
of which include standards and guidelines for clinical trials (and
their data) set out by the International Committee ofMedical Jour-
nal Editors and the Declaration of Helsinki, among others. (Inter-
national Standards for Clinical Trial Registries, Version 3.0.
Geneva: WHO, 2018. License: CC BY-NC-SA 3.0 IGO.) To record
data in a consistent manner, datasets and metadata annotations
are entered into the database by hPSCreg staff. Registered users
of hPSCreg are also allowed to enter new clinical studies; however,
hPSCreg staff will check the information before it will be publicly
displayed on the hPSCreg clinical studywebsite. In the case of clin-
ical studies involving hPSCs, information pertinent to the respec-
tive cell products, such as the cell line provenance from the source
hPSC line to its hPSC-derived therapeutic product, are not manda-
tory information in the TRDS. This value-added information is
manually collected by hPSCreg staff through public sources. Being
currently not mandatory because this information is not available
for some hiPSC-based cell products, hPSCreg aims at making this
source cell information mandatory for new trials, and retrospec-
tively for already registered trials. Finally, hPSCreg reaches out to
qualified investigators of the clinical studies for verification of
the collected data and additional updates. Data records, which
have been further validated by contact with qualified investigators
of the studies, are marked as such in the database to demonstrate
the extra level of confirmation. A complete overview of the clinical
study data sourcing process is shown in Figure S1.
Persons in charge of a study whowould like to add a new clinical
study to the database are encouraged to visit the hPSCregweb page
and to contact hPSCreg through the respective form (https://
hpscreg.eu/contact).SUPPLEMENTAL INFORMATION
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